Insilico Medicine will partner with SK Biopharmaceuticals to discover new artificial intelligence (AI)-based drug candidates for disorders affecting the neuroimmune area of the central nervous system ...
The stock has soared more than 220% in three years.
Driven by personal losses, major unmet needs and a desire to diversify from the crowded oncology market, Fosun Pharma is ...
What if the vast amounts of data generated by molecular dynamics simulations could be routinely shared and reused? A new €10 ...
Fasting blood tests measuring GLP-1 and GIP levels may predict obesity treatment response to semaglutide and tirzepatide, ...
May was the busiest month of the year so far for U.S. FDA drug approvals, pushing the year-to-date total to 84 approvals and 20 new molecular entities through five months. Globally, drug approvals ...
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026Affirms 2026 guidance on key milestones Reports ...
Enabled Design of a Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation in Parkinson's Disease," will detail how the company's Hybrid AI Platform, built together with Expert Systems, Inc., guided ...
Yuhan announced Tuesday that its drug candidate YH35995, under development as a treatment for Gaucher disease, has received ...
BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with ...
A controversial lawmaker, has called for accountability, following the interception in Australia of a large consignment of ...
Can newly identified antiviral compounds help stop some of the most dangerous mosquito-borne viruses that attack the brain? A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results